
X
NHS England takes charge on market access
https://pharmaphorum.com/views-analysis-market-access/perjeta-benefits-nhs-england-takes-charge/
Market Access
Should there be a different review of NICE as part of a successor PPRS?
NICE recommends two-year trial of Gaia Healthcare product
Janssen’s UK pricing chief Jennifer Lee has called for reform of NICE following the company’s successful but drawn-out attempt to get its cancer drug Darzalex to NHS patients.
The cost: benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them.
Public health experts and UK life science leaders are reiterating concerns about Brexit’s threat to the nation’s health.